Anzeige
Mehr »
Mittwoch, 29.04.2026 - Börsentäglich über 12.000 News
Zuerst +50%… jetzt ein $20M Graphen-Deal
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

OMX Copenhagen 25 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktuelle News zu Aktien im OMX Copenhagen 25

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
00:19Health Canada approves first generic version of Ozempic4
DiAbnehmwunder made in Germany: Dieses deutsche Familienunternehmen will Novo und Lilly vom Thron stoßen776© Foto: Helmut Fricke - dpaNicht weniger Kilos, sondern bessere Kilos - das ist das Versprechen, mit dem Boehringer Ingelheim in den milliardenschweren Markt für Abnehmmittel drängt. Das Ingelheimer...
► Artikel lesen
DiKURSZIEL ANGEHOBEN bei Novo nordisk: Was Insider heute bereits wissen - Meine klare Einschätzung dazu
DiCan Oral Ozempic and Label Expansions Revive NVO's Near-Term Growth?33
DiNovo Nordisk A/S: Novo Nordisk to present new data on Wegovy, women with obesity and next-generation weight loss treatments at European Congress on Obesity1.802Analyses of the higher dose of Wegovy (semaglutide 7.2 mg) and Wegovy pill (oral semaglutide 25 mg) show how fast and how much sustained weight loss people who responded early to treatment achievedWegovy...
► Artikel lesen
DiNOVO NORDISK A/S - Stabilität mit strategischer Tiefe19
DiTryg A/S: Tryg recognises a one-off impact of DKK 1.2bn pre-tax related to Supreme Court ruling on Danish workers' compensation127Today, the Danish Supreme Court ruled on a precedent-setting case regarding workers' compensation in Denmark, which affects the entire insurance industry as well as the State and municipalities in Denmark....
► Artikel lesen
DiIs This Deal a Game Changer for Novo Nordisk?85
DiErfolg in Phase-3-Studie: Survodutid von Zealand Pharma erzielt 16,6 % Gewichtsverlust12
DiZealand Pharma: Survodutide erzielt 16,6 % Gewichtsverlust in Phase-III-Studie17
DiZealand Pharma's survodutide shows 16.6% weight loss in trial5
DiZealand Pharma's survodutide achieves 16.6% weight loss in trial3
DiZealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people with obesity or overweight in Phase 3 trial352Company announcement - No. 10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic...
► Artikel lesen
DiCentral Vietnam hub Danang deepens cooperation with Maersk on Lien Chieu port, logistics2
MoProthena Corporation plc: Prothena Announces Novo Nordisk Obtains Fast Track Designation from the U.S. FDA for Coramitug (PRX004) in ATTR Amyloidosis with Cardiomyopathy437 Coramitug is a potential best-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 Coramitug is being evaluated by Novo Nordisk in the ongoing Phase...
► Artikel lesen
MoMaersk lines up Med-Baltic SLA loop from Tanger Med4
MoVestas wins 186MW Quebec turbine order10
MoA.P. Møller - Mærsk A/S: Transactions in connection with share buy-back program2
MoVestas stärkt Präsenz in Nord Amerika5
MoVESTAS WIND SYSTEMS A/S: Vestas strengthens Québec presence with 186 MW order from EDF power solutions North America6
Weiter >>